Cargando…

Primary Cutaneous Mucinous Carcinoma Monitoring: A Role for CA15.3 and CEA?

Primary cutaneous mucinous carcinoma (PCMC) is a rare malignant skin adnexal tumor. Recurrences are most often localized, and long-term follow-up after complete surgery consists essentially of self-examination of skin. We report one case of metastatic PCMC with elevated levels of serum CEA and CA15....

Descripción completa

Detalles Bibliográficos
Autores principales:	Ginguay, Antonin, Kramkimel, Nora, Lecolant, Solène, Goldwasser, François, Battistella, Maxime, Arrondeau, Jennifer
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	S. Karger AG 2022
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9841795/ https://www.ncbi.nlm.nih.gov/pubmed/36655184 http://dx.doi.org/10.1159/000525524

Ejemplares similares

Intensive post-operative follow-up of breast cancer patients with tumour markers: CEA, TPA or CA15.3 vs MCA and MCA-CA15.3 vs CEA-TPA-CA15.3 panel in the early detection of distant metastases
por: Nicolini, Andrea, et al.
Publicado: (2006)

Different Levels of CEA, CA153 and CA125 in Milk and Benign and Malignant Nipple Discharge
por: Zhao, Song, et al.
Publicado: (2016)

The prognostic role of variations in tumour markers (CEA, CA15.3) in patients with metastatic breast cancer treated with CDK4/6 inhibitors
por: Sottotetti, Federico, et al.
Publicado: (2022)

Serum CA19‐9, CA‐125 and CEA as tumor markers for mucinous ovarian tumors
por: Lertkhachonsuk, Arb‐aroon, et al.
Publicado: (2020)

Soluble POSTN is a novel biomarker complementing CA153 and CEA for breast cancer diagnosis and metastasis prediction
por: Jia, Li, et al.
Publicado: (2022)

Diagnostic impact of CEA and CA 15-3 on chemotherapy monitoring of breast cancer patients
por: Hasan, Diya
Publicado: (2022)

Epithelial mucin core antigen (EMCA) in assessing therapeutic response in advanced breast cancer--a comparison with CA15.3.
por: Dixon, A. R., et al.
Publicado: (1993)

Serum Markers CA125, CA153, and CEA along with Inflammatory Cytokines in the Early Detection of Lung Cancer in High-Risk Populations
por: Li, Guangping, et al.
Publicado: (2022)

An updated evaluation of serum sHER2, CA15.3, and CEA levels as biomarkers for the response of patients with metastatic breast cancer to trastuzumab-based therapies
por: Perrier, Alexandre, et al.
Publicado: (2020)

Prognostic value of monitoring tumour markers CA 15-3 and CEA during fulvestrant treatment
por: Bartsch, Rupert, et al.
Publicado: (2006)

Clinical Significance of CYFRA21-1, AFP, CA-153, CEA, and CA-199 in the Diagnosis of Lung Cancer Ocular Metastasis in Hypertension Population
por: Tang, Jing, et al.
Publicado: (2021)

Serum CA549 in primary breast cancer: comparison with CA15.3 and MCA.
por: Gion, M., et al.
Publicado: (1994)

Detection of secondary metastatic breast cancer by measurement of plasma CA 15.3
por: De Cock, L., et al.
Publicado: (2021)

Serum CEA and CA 15-3 as prognostic factors in primary breast cancer
por: Ebeling, F G, et al.
Publicado: (2002)

CA15.3 Serum Concentrations in Older Women with Infiltrating Ductal Carcinomas of the Breast
por: Ruibal, Álvaro, et al.
Publicado: (2014)

Diagnostic and prognostic significance of different mucin expression, preoperative CEA, and CA-125 in colorectal carcinoma: A clinicopathological study
por: Jain, Parul, et al.
Publicado: (2014)

The tumour associated antigen CA15.3 in primary breast cancer. Evaluation of 667 cases.
por: Gion, M., et al.
Publicado: (1991)

Symptomatic metastasis prediction with serial measurements of CA 15.3 in primary breast cancer patients
por: Bahrami-Ahmadi, Amir, et al.
Publicado: (2012)

Polymorphisms of MUC16 (CA125) and MUC1 (CA15.3) in Relation to Ovarian Cancer Risk and Survival
por: Williams, Kristina A., et al.
Publicado: (2014)

The value of KRAS mutation testing with CEA for the diagnosis of pancreatic mucinous cysts
por: Kadayifci, Abdurrahman, et al.
Publicado: (2016)

Concordance of Hypermethylated DNA and the Tumor Markers CA 15-3, CEA, and TPA in Serum during Monitoring of Patients with Advanced Breast Cancer
por: Kristiansen, Søren, et al.
Publicado: (2015)

Association of Preoperative Serum Levels of CEA and CA15-3 with Molecular Subtypes of Breast Cancer
por: Zhao, Wenjing, et al.
Publicado: (2021)

Nipple Discharge of CA15-3, CA125, CEA and TSGF as a New Biomarker Panel for Breast Cancer
por: Wang, Gangping, et al.
Publicado: (2014)

Diagnostic Utility of Combined CEA, CA15-3 and CA125 Biomarkers and Cytomorphology in Suspicious and Malignant Serosal Fluid
por: Rahemi, Zahra, et al.
Publicado: (2021)

Combined Evaluation of AFP, CA15-3, CA125, CA19-9, and CEA Tumor Markers in Patients with Hepatitis B and C
por: ASSMAR, Mehdi, et al.
Publicado: (2016)

Use of CEA and CA15-3 to Predict Axillary Lymph Node Metastasis in Patients with Breast Cancer
por: Wu, San-Gang, et al.
Publicado: (2016)

Menstrual Cycle Dependent Variability for Serum Tumor Markers CEA, AFP, CA 19-9, CA 125 and CA 15-3 in Healthy Women
por: Erbağci, Ayşe Binnur, et al.
Publicado: (1999)

Nomograms for Predicting the Prognostic Value of Pre-Therapeutic CA15-3 and CEA Serum Levels in TNBC Patients
por: Dai, Danian, et al.
Publicado: (2016)

Combined detection of CA15-3, CEA, and SF in serum and tissue of canine mammary gland tumor patients
por: Fan, Yuying, et al.
Publicado: (2021)

Clinical utility of tumour marker velocity of cancer antigen 15–3 (CA 15–3) and carcinoembryonic antigen (CEA) in breast cancer surveillance
por: Hing, J.X., et al.
Publicado: (2020)

Evaluation of serum CA15-3 determination with CEA and TPA in the post-operative follow-up of breast cancer patients.
por: Nicolini, A., et al.
Publicado: (1991)

Carbon Nanopowder-Based Stochastic Sensor for Ultrasensitive Assay of CA 15-3, CEA and HER2 in Whole Blood
por: Stefan-van Staden, Raluca-Ioana, et al.
Publicado: (2022)

FTO, PIK3CB serve as potential markers to complement CEA and CA15-3 for the diagnosis of breast cancer
por: Mi, Jintao, et al.
Publicado: (2023)

Preoperative serum levels of CEA and CA 242 in colorectal cancer.
por: Carpelan-Holmström, M., et al.
Publicado: (1995)

The Clinical Significance of CEA, CA19–9, and CA125 in Management of Appendiceal Adenocarcinoma
por: Yousef, Abdelrahman, et al.
Publicado: (2023)

sFlt-1 and CA 15.3 are indicators of endothelial damage and pulmonary fibrosis in SARS-CoV-2 infection
por: Greco, Marilena, et al.
Publicado: (2021)

Population Pharmacokinetics/Pharmacodynamics of Dabrafenib Plus Trametinib in Patients with BRAF-Mutated Metastatic Melanoma
por: Balakirouchenane, David, et al.
Publicado: (2020)

Elevated Levels of Serum Tumor Markers CEA and CA15-3 Are Prognostic Parameters for Different Molecular Subtypes of Breast Cancer
por: Shao, Yingbo, et al.
Publicado: (2015)

Improved sensitivity for detection of breast cancer by combination of miR-34a and tumor markers CA 15-3 or CEA
por: Zaleski, Martin, et al.
Publicado: (2018)

Monitoring of postoperative neutrophil-to-lymphocyte ratio, D-dimer, and CA153 in: Diagnostic value for recurrent and metastatic breast cancer
por: Ren, Zhiyao, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_87e49l9udao5an42kntd40536e